Altitude Life Science Ventures Fund II L.P. 13D and 13G filings for eFFECTOR Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-05 4:15 pm Purchase | 2023-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR | Altitude Life Science Ventures Fund II L.P. | 2,826,350 4.400% | 2,713,296 (+2400.00%) | Filing |
| 2023-03-07 5:25 pm Purchase | 2021-08-25 | 13G | eFFECTOR Therapeutics, Inc. EFTR | Altitude Life Science Ventures Fund II L.P. | 113,054 6.700% | 113,054 (New Position) | Filing |